Quintiles projects increase in biopharma R&D spending

Quintiles projects increase in biopharma R&D spending Consider the trend for GlaxoSmithKline (NYSE: GSK), which entered the cliff slightly earlie...


Quintiles projects increase in biopharma R&D spending
Consider the trend for GlaxoSmithKline (NYSE: GSK), which entered the cliff slightly earlier than some others in Big Pharma. In 2006, a group of eight drugs – including Wellbutrin, Lamictal, Zofran and Paxil – made up 18 percent of all sales. By 2009 …
Read more on Triangle Business Journal

Leave a Reply